Bavarian Nordic scores $157M contract to replenish US supplies of smallpox/mpox vaccine Jynneos

Following the commercial launch of Bavarian Nordic’s smallpox/mpox vaccine Jynneos earlier this year, the Danish company has locked up yet another supply agreement with the U.S. government.

The Biomedical Advanced Research and Development Authority (BARDA) is handing Bavarian Nordic $156.8 million to “partly replenish” vaccine stocks in response to the 2022 outbreak of mpox, the disease formerly known as monkeypox.